- Home
- MPU vs CMRX Comparison
MPU vs CMRX Comparison
Compare MPU & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPU
- CMRX
- Stock Information
- Founded
- MPU 1989
- CMRX 2000
- Country
- MPU Singapore
- CMRX United States
- Employees
- MPU N/A
- CMRX N/A
- Industry
- MPU Transportation Services
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- MPU Consumer Discretionary
- CMRX Health Care
- Exchange
- MPU Nasdaq
- CMRX Nasdaq
- Market Cap
- MPU 66.0M
- CMRX 77.1M
- IPO Year
- MPU 1998
- CMRX 2013
- Fundamental
- Price
- MPU $1.71
- CMRX $2.79
- Analyst Decision
- MPU
- CMRX Strong Buy
- Analyst Count
- MPU 0
- CMRX 2
- Target Price
- MPU N/A
- CMRX $8.50
- AVG Volume (30 Days)
- MPU 115.9K
- CMRX 11.2M
- Earning Date
- MPU 11-12-2024
- CMRX 11-07-2024
- Dividend Yield
- MPU N/A
- CMRX N/A
- EPS Growth
- MPU N/A
- CMRX N/A
- EPS
- MPU N/A
- CMRX N/A
- Revenue
- MPU $26,001,000.00
- CMRX $159,000.00
- Revenue This Year
- MPU N/A
- CMRX N/A
- Revenue Next Year
- MPU N/A
- CMRX $1,690.28
- P/E Ratio
- MPU N/A
- CMRX N/A
- Revenue Growth
- MPU 1444400.00
- CMRX N/A
- 52 Week Low
- MPU $0.77
- CMRX $0.75
- 52 Week High
- MPU $4.48
- CMRX $3.39
- Technical
- Relative Strength Index (RSI)
- MPU 50.01
- CMRX 84.35
- Support Level
- MPU $1.66
- CMRX $2.74
- Resistance Level
- MPU $1.79
- CMRX $3.02
- Average True Range (ATR)
- MPU 0.13
- CMRX 0.26
- MACD
- MPU -0.02
- CMRX 0.18
- Stochastic Oscillator
- MPU 15.63
- CMRX 77.13
About MPU Mega Matrix Corp.
Mega Matrix Inc formerly Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.